Investigational drug · Phase 2
ALV-100
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Overweight , Obesity, Adults.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ALV-100"
First trial start
2026
Aug 10, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALV-100", any sponsor or status.
Conditions studied
As listed on its trial records.
- Overweight , Obesity
- Adults
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "ALV-100" as an intervention, largest first.
- Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight LossPivotal-lookingRecruiting
Alveus Therapeutics, Inc.Industry
NCT07837973 · 220 participants (planned) · Start Aug 10, 2026 · Primary completion Aug 24, 2027
Drug: ALV-100; Placebo · For: Overweight , Obesity; Adults
Sites: Birmingham, Alabama; Sun City, Arizona; Tempe, Arizona · 20 sites in all
- Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2DPivotal-lookingActive, not recruiting
Alveus Therapeutics, Inc.Industry
NCT07399678 · 180 participants (planned) · Start Dec 29, 2025 · Primary completion Oct 2027
Drug: ALV-100; Placebo · For: Overweight or Obese Adults; Overweight or Obese, Type 2 Diabetes
Sites: Miami, Florida; Columbus, Ohio; San Antonio, Texas
Debiopharm International SAIndustry
NCT02094443 · 52 participants · Start Mar 2014 · Primary completion Apr 2015
Drug: Alisporivir; Ribavirin · For: Hepatitis C; Liver Disease
Sites: Bakersfield, California; Lancaster, California; San Diego, California · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Overweight , Obesity
- EcnoglutideXW003, VRB-101Phase 38 trials
Hangzhou Sciwind Biosciences Co., Ltd. · Obesity, Weight Management, OSA - Obstructive Sleep Apnea
- MWN109 1Phase 36 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- MWN109 2Phase 36 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- MWN109 3Phase 35 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- zovaglutideZT002Phase 33 trials
Beijing QL Biopharmaceutical Co.,Ltd · Obesity, Overweight , Obesity, Overweight or Obesity
- matching dosagePhase 22 trials
Hangzhou Sciwind Biosciences Co., Ltd. · Weight Management, Overweight , Obesity, Overweight and/or Obesity
- MWN109 4Phase 22 trials
Shanghai Minwei Biotechnology Co., Ltd · Type 2 Diabetes Mellitus (T2DM), Overweight , Obesity
- SRSD384Phase 21 trial
Sirius Therapeutics Co., Ltd. · Overweight , Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.